TABLE 1

Patient characteristics at registration for lung transplantation

	Airway dilatation− n=16	Airway dilatation+ n=22	p-value
Male	9 (56)	9 (41)	0.35
Age, years	33 (14–47)	25 (15–42)	0.43
Height, cm	158 (141–169)	159 (143–164)	0.89
Weight, kg	39.3 (25.7–50.6)	40.0 (28.9–49.6)	0.70
Ex-smokers	1 (6)	3 (14)	0.46
Causes of BO
HSCT	14 (88)	20 (91)	0.74
Lung transplantation	2 (13)	2 (9)
Bilateral/right/left	0 (0)/1 (6)/1 (6)	2 (9)/0 (0)/0 (0)
BO with prominent fibrosis	3 (19)	1 (5)	0.16
Prednisolone use	11 (69)	19 (86)	0.19
Dose, mg·day⁻¹	15 (7.5–15)	8 (4.0–12.5)	0.13
Immunosuppressive agent use	6 (38)	12 (55)	0.30
Inhaled corticosteroid use	10 (63)	12 (55)	0.62
Time from the causes of BO to diagnosis of BO, year	2.3 (0.8–5.2)	1.3 (0.7–2.9)	0.17
Time from the diagnosis of BO to registration, years	1.5 (0.6–4.1)	2.8 (1.1–6.0)	0.15
Age at diagnosis of BO, years	31 (13–44)	21 (12–37)	0.31
Time from registration to lung transplantation^#, months	2.4 (0.6–18.8)	1.5 (1.2–17.3)	0.73
Pulmonary function test^¶
FVC, % of predicted	48.3 (16.3–68.4)	46.5 (38.9–50.8)	1.00
FEV₁, % of predicted	20.1 (16.7–44.0)	22.0 (18.3–23.0)	0.76
FEV₁/FVC, %	68.5 (35.0–96.1)	42.7 (34.5–50.1)	0.15
RV, % of predicted	87.0 (54.6–166.2)	176.8 (131.7–236.1)	0.03
RV/TLC, %	46.4 (41.9–50.8)	53.2 (46.9–58.9)	0.12
Pneumonia within the previous year	6 (38)	8 (36)	0.94
Reiff score	0	7 (4–10)	–

BO: bronchiolitis obliterans; HSCT: hematopoietic stem-cell transplantation; FVC: forced vital capacity; FEV₁: forced expiratory volume in 1 s; RV: residual volume; TLC: total lung capacity. All values are expressed as median (interquartile range) except categorical variables, which are expressed as n (%).

^#29 patients received living-donor lung transplantation.

^¶Available for 21 patients (airway dilatation+ n=12, airway dilatation− n=9).